| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people |
|
Medicine details |
|
| Medicine name | secukinumab (Cosentyx®) |
| Formulation | subcutaneous injection |
| Reference number | 4009 |
| Indication | Treatment of moderate to severe plaque psoriasis in children aged 6 < 18 years old, who are candidates for systemic therapy |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/12/2020 |
| NICE guidance | TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people |